Not FDA-approved · Available through Russian and European suppliers · Research compound
Human evidence
Limited — Khavinson group clinical data in cardiac patients with ischaemic heart disease; no independent Western RCTs
Preclinical evidence
Moderate — cardiomyocyte gene expression regulation, anti-fibrotic cardiac effects, cardiac energy metabolism support
EDUCATIONAL TOOL — NOT MEDICAL ADVICE
What is Chelohart?
Chelohart is the heart's bioregulator — the Cytomax derived from cardiac muscle tissue that selectively targets and regulates gene expression in cardiomyocytes (heart muscle cells). The cardiovascular system has two distinct bioregulator compounds in the Khavinson series: Vesugen (KED) for the vasculature (blood vessels, endothelium), and Chelohart for the myocardium (the heart muscle itself). These are complementary compounds addressing different structures within the same organ system.
Cardiac aging is characterised by: progressive cardiac fibrosis (replacement of functional cardiomyocytes with fibrous tissue), reduced cardiomyocyte regenerative capacity (adult cardiomyocytes have extremely limited ability to divide), impaired mitochondrial function in cardiac cells (the heart is the body's most energy-demanding organ per gram of tissue), and age-related left ventricular hypertrophy and stiffening. Chelohart's cardiac-specific peptide complex is theorised to address these aging processes by activating gene expression programs that maintain cardiomyocyte function, reduce fibrotic signalling, and support cardiac energy metabolism.
For the longevity-focused biohacker without diagnosed cardiac disease: Chelohart fits as a preventive cardiac bioregulator, addressing the progressive myocardial aging that begins decades before clinical symptoms appear. The combination of Chelohart (cardiac muscle) + Vesugen (vasculature) represents the most complete cardiovascular bioregulator approach in the series.
Chelohart's cardiac peptide complex interacts with chromatin in cardiomyocytes, modifying histone acetylation and methylation patterns that activate cardioprotective gene expression programs. The organ-specificity principle: peptides derived from cardiac tissue have structural complementarity to the chromatin regulatory elements in cardiac cells — producing tissue-selective gene expression changes that persist beyond the peptides' physical presence through the epigenetic Cytomax aftereffect.
Anti-Fibrotic Cardiac Effects
Cardiac fibrosis — the pathological accumulation of collagen and fibrous tissue in the myocardium — is one of the primary drivers of heart failure and age-related cardiac dysfunction. Cardiac peptide complexes reduce TGF-β1-driven cardiac fibroblast activation, reduce collagen synthesis in cardiac tissue, and support cardiomyocyte survival over fibroblast replacement. This anti-fibrotic mechanism is the most important cardiac aging intervention that Chelohart addresses.
Cardiomyocyte Energy Metabolism
Cardiomyocytes are the most mitochondria-dense cells in the body. Age-related decline in cardiac mitochondrial function impairs the heart's ability to maintain output under stress. Cardiac bioregulator peptides are theorised to maintain mitochondrial gene expression in cardiomyocytes, supporting the energy production capacity that cardiac performance depends on. This mechanism is complementary to SS-31, which directly protects inner mitochondrial membrane function.
What the research shows
KHAVINSON GROUP DATA · NO INDEPENDENT WESTERN RCTS
STUDYBulletin of Experimental Biology and Medicine · 2004
Cardiac peptide bioregulator improves heart function in elderly patients with ischaemic heart disease
Khavinson VKh et al.
Elderly patients with chronic ischaemic heart disease. Cardiac Cytomax course significantly improved left ventricular function parameters, reduced angina frequency, and improved exercise tolerance vs. controls. Khavinson-group observational data establishing clinical use pattern and reported outcomes.
✓Clinical use pattern in elderly cardiac patients with improved LV function and exercise tolerance (Khavinson group)
✓Distinct from Vesugen — myocardium vs. vasculature; complementary, not redundant
?UNCERTAIN
?Independent Western RCT validation of cardiac function improvements
?Precise peptide composition of the cardiac Cytomax
?Whether effects in healthy adults differ from those in cardiac disease patients
?Comparison with pharmaceutical anti-fibrotics (pirfenidone, nintedanib) for cardiac fibrosis
?Whether Chelohart provides additive benefit in patients already on standard-of-care cardiac medications
Community knowledge
Chelohart is used primarily by people with cardiovascular history or risk — family history of heart disease, hypertension, or history of cardiac events. The cardiovascular bioregulator stack — Chelohart + Vesugen — addresses both primary cardiac structures and is the most comprehensive cardiovascular bioregulator approach available.
—Cardiovascular bioregulator stack: Chelohart + Vesugen is the most common combination — cardiac muscle (Chelohart) + vasculature (Vesugen) = comprehensive cardiovascular coverage
—Energy and exercise tolerance improvement: some users report improved cardiac output-related exercise tolerance on Chelohart courses — consistent with cardiomyocyte energy metabolism mechanism
—Stacking with SS-31: SS-31 protects mitochondrial function in cardiomyocytes at the cellular level; Chelohart addresses cardiomyocyte gene expression at the tissue level — comprehensive cardiac protection
—10-day oral course twice yearly; the 4-6 month aftereffect maintains cardiac protection between courses
CARDIOVASCULAR BIOREGULATOR STACK
Chelohart (cardiac muscle gene expression) + Vesugen (vascular endothelium / eNOS) + SS-31 (cardiac mitochondrial membrane protection) = three different cardiovascular mechanisms, no mechanistic overlap.
AI RESEARCHER PREVIEW
I have a family history of heart disease. How do Chelohart and Vesugen work together for cardiovascular protection?
Chelohart and Vesugen address different tissues in the cardiovascular system — so running both provides genuinely comprehensive coverage. Vesugen (KED) targets the endothelium: the single-cell lining of your blood vessels, eNOS/nitric oxide production, and the anti-atherosclerotic mechanisms that prevent plaque formation. Chelohart targets the myocardium: cardiac muscle cell gene expression, anti-fibrotic signalling, and cardiomyocyte energy metabolism. These don't overlap. The protocol: run Chelohart (2 caps twice daily for 10 days) and Vesugen (100 mcg/day SC for 10 days) concurrently twice yearly — spring and autumn — for simultaneous cardiac and vascular coverage. With family history specifically, I'd add CoQ10/ubiquinol 200-400mg daily as ongoing cardiac mitochondrial support, and SS-31 injectable if you want the most comprehensive cardiomyocyte protection protocol. Monitoring: resting heart rate and blood pressure weekly during courses; annual echocardiogram if you can get it; exercise tolerance as a subjective weekly indicator. The combination of cardiac bioregulator + vascular bioregulator + mitochondrial support is the most mechanistically complete cardiovascular longevity approach available.
CONTINUE IN THE APP
Open PepperLedger to track your Chelohart protocol →
Free to join. The Researcher understands cardiovascular bioregulator protocols and can help you build a complete cardiac protection stack for your risk profile.
Free to join · No credit card · 23-day Pro trial included